ライフサイエンスコーパス: posttransplant

1 pletion of the parent STN study at 24 months posttransplant).

2 , and alanine aminotransferase within 3 days posttransplant.

3 h 33% higher mortality beyond the third year posttransplant.

4 ive study of 46 patients with HCV recurrence posttransplant.

5 s administered subcutaneously on days 0 to 5 posttransplant.

6 lar filtration rates at 1, 2, 3, and 4 years posttransplant.

7 lower viral infections, and low relapse rate posttransplant.

8 ll numbers from pretransplant until 15 years posttransplant.

9 galovirus occurred at 5.6 (0.63-27.7) months posttransplant.

10 n A levels were measured in plasma at day 30 posttransplant.

11 0% continuing to have circulating antibodies posttransplant.

12 outpatient expenditures in the first 3 years posttransplant.

13 tology from biopsies approximately 12 months posttransplant.

14 is an ongoing need to circumvent islet loss posttransplant.

15 acute rejection (BPAR) during the first year posttransplant.

16 r marrow transplants and VCA at 5 to 7 weeks posttransplant.

17 let-KC mice (n = 15 of 16) became euglycemic posttransplant.

18 o patients had at least 1 infectious episode posttransplant.

19 ents had at least 1 positive culture for NTM posttransplant.

20 % of all patients continue or resume smoking posttransplant.

21 median 1038 days (range, 165-3706) follow-up posttransplant.

22 t recovered high levels of catalytic Abs 2 y posttransplant.

23 the ability to engraft in patients by day 42 posttransplant.

24 prior transplantation, whereas it did 12 mo posttransplant.

25 samples per patient, over 7.4 +/- 4.4 years posttransplant.

26 re noted at 3 months, and 1, 5, and 10 years posttransplant.

27 753 (20%) had IBx at a median of 15.3 months posttransplant.

28 urred at a median time of 3.4 (0-19.8) years posttransplant.

29 a median time of 65.5 months (2-183 months) posttransplant.

30 a prominent feature in both groups long-term posttransplant.

31 and 100% of the mice within 6.8 to 18.5 days posttransplant.

32 K cells were infused on days -2, +7, and +28 posttransplant.

33 l and absolute lymphocyte count up to 1 year posttransplant.

34 without RBV in patients with HCV recurrence posttransplant.

35 eration and restoration of adaptive immunity posttransplant.

36 al of 13 unexpected grade 3-5 adverse events posttransplant (10 grade 3 and 3 grade 4 events).

37 MV-free survival rates at 1 year and 3 years posttransplant (100%) were significantly (p = 0.015) hig

38 ng/mortality, hospital duration, and 3-month posttransplant 6MWD were evaluated using Fisher exact te

39 = 0.04), but not with delisting/mortality or posttransplant 6MWD.

40 At 12 months posttransplant 9 of 10 were C-peptide positive, (5 insul

41 his overview focuses on the risk factors for posttransplant acute kidney injury after liver and heart

42 tion of the study ("chronic") or for 4 weeks posttransplant ("acute").

43 ences of age at transplantation and attained posttransplant age on mortality hazard among patients st

44 However, reports of successful prevention of posttransplant aHUS recurrence with eculizumab emerged a

45 t of variation (CV) measured between 1 month posttransplant and the clinical event, with a comparable

46 d for DSA pretransplant, monitored regularly posttransplant and when clinically indicated using the s

47 remained hospitalized for more than 4 weeks posttransplant, and 20% were discharged to an acute care

48 receiving this regimen approximately 4 years posttransplant, and histology from biopsies approximatel

49 idney disease, was withdrawn within 2 months posttransplant, and no de novo immunosuppression was giv

50 risk of BOS was observed in recipients with posttransplant anxiety (HR, 0.61; 95%CI, 0.37-1.00).

51 associated with poor outcomes, screening for posttransplant anxiety should also be routine, to reduce

52 At 3-6 months posttransplant, belatacept-treated patients were re-rand

53 d rejection was present in 13 (52%) 25 early posttransplant biopsies from ABOi recipients by immunohi

54 s correlates significantly with incidence of posttransplant BK viremia.

55 Eighty-five recipients (40%) had posttransplant BK viruria including 61 with additional v

56 tivity was assessed in 280 pretransplant and posttransplant blood samples from 33 desensitized patien

57 One patient experienced posttransplant C3 glomerulonephritis.

58 Of 329 OTRs with an index posttransplant cancer (100 women and 229 men; mean [SD]

59 ; 95% CI, 1.2-3.7), skin cancer as the index posttransplant cancer (subhazard ratio, 5.5; 95% CI, 2.5

60 , patients taking sirolimus after developing posttransplant cancer had a lower risk of developing sub

61 Our objective was to assess the risk of posttransplant cancer in this patient group.

62 were reviewed for OTRs diagnosed as having a posttransplant cancer of any type to determine the type

63 Posttransplant cancer risk and survival rates of these p

64 ors of skin cancer formation after the index posttransplant cancer were history of pretransplant skin

65 ype of organ transplanted, pretransplant and posttransplant cancer, and immunosuppressive medications

66 s, almost half of the patients experienced a posttransplant cancer.

67 OTRs or those already diagnosed as having a posttransplant cancer.

68 transplant cancer showed higher incidence of posttransplant cancers and shorter survival compared wit

69 hundred thirty OTRs (39.5%) developed second posttransplant cancers, of which 115 cases (88.5%) were

70 Posttransplant cardiovascular complications were identif

71 t smokers had higher odds of newly developed posttransplant cardiovascular disease (OR, 1.41; 95% CI,

72 5607 million to $5569 million, p < 0.03) and posttransplant care ($479 million to $488 million, p < 0

73 nce to prescribed therapy, pretransplant and posttransplant care, implementation of clinical guidelin

74 fy depression should therefore be routine in posttransplant care.

75 e important in determining the likelihood of posttransplant cholangiopathy.

76 for efficacy, timing relative to transplant, posttransplant clinical outcomes, and cost.

77 of this study is to analyze risk factors for posttransplant CMV infection and to assess the efficacy

78 TAC attenuated weight gain at 1 and 2 years posttransplant compared with a standard TAC immunosuppre

79 mortality and graft loss for up to 15 years posttransplant, controlling for other known risk factors

80 ent identified patients at increased risk of posttransplant coronary events and was also useful to de

81 ut reports on temporal trends in the risk of posttransplant cutaneous squamous cell carcinoma (SCC) a

82 The use of posttransplant cyclophosphamide (PT-Cy) as graft-versus-

83 itioning haploidentical transplantation with posttransplant cyclophosphamide does not compromise earl

84 Haploidentical recipients received posttransplant cyclophosphamide-based graft-versus-host

85 d reduced-intensity conditioning regimen and posttransplant cyclophosphamide-based graft-versus-host

86 Late AMR (median posttransplant day 323) was diagnosed in 5 of 36 recipie

87 ) recipients diagnosed with early (first 180 posttransplant days) IPA at 19 institutions between 2000

88 her differences in survival and incidence of posttransplant de novo malignancies exist between recipi

89 The pooled HR for developing posttransplant de novo malignancy was also increased (HR

90 cer-specific mortality, and (3) incidence of posttransplant de novo malignancy.

91 y endpoint was a 3-year composite outcome of posttransplant death or major cardiovascular event (myoc

92 vivo kidney perfusion might help to decrease posttransplant delayed graft function rates and to incre

93 Associations with pretransplant and posttransplant delisting/mortality, hospital duration, a

94 Recipients with posttransplant depression had an elevated risk of BOS (h

95 Early posttransplant depression increases risk for long-term t

96 Optimal posttransplant dermatologic care may be determined based

97 toxicity-negative crossmatch, who received a posttransplant desensitization protocol starting at day

98 500 and 3000 at day 0) who received the same posttransplant desensitization.

99 dy the breakthrough alloresponse that occurs posttransplant despite immunoprophylaxis and to develop

100 l genetic polymorphisms modulate the risk of posttransplant diabetes mellitus (PTDM), a complication

101 pletion, low-dose total body irradiation and posttransplant (donor) bone marrow, and splenocyte infus

102 ism in hepatic and renal failure, as well as posttransplant drug-drug interactions.

103 We initiated a routine posttransplant DSA monitoring and surveillance biopsy pr

104 home and to develop effective strategies for posttransplant education.

105 antiaging glycopeptide (AAGP) would enhance posttransplant engraftment and function and protect agai

106 Recent studies reported that posttransplant Epstein-Barr virus (EBV) replication is f

107 Non-HLA antibody testing was included in the posttransplant evaluation for 70 kidney recipients.

108 poses, providing insight in risk factors for posttransplant events, and as baseline for comparison wi

109 After a median posttransplant follow-up of 50.9 months, hepatocellular

110 % incidence of malignant tumors after a mean posttransplant follow-up of 7.9 +/- 5.4 years.

111 Posttransplant follow-up should take the HEHE-LT score i

112 Median duration of posttransplant follow-up was 12.5 (3-19) years.

113 ents initiating once-daily tacrolimus during posttransplant follow-up were analyzed.

114 During the posttransplant follow-up, these LTRs displayed HCMV DNA

115 In the first year posttransplant for KDPI greater than 85% of transplants

116 The best histological predictor for posttransplant glomerular filtration rate in the LAT gro

117 icantly higher in perfusates of kidneys with posttransplant graft dysfunction (primary nonfunction an

118 r histones might contribute to assessment of posttransplant graft function and survival.

119 Ten-year posttransplant graft survival was 68.5%, 63.6%, and 65.7

120 -related complications such as infection and posttransplant graft-versus-host disease.

121 tand which patients are more likely to smoke posttransplant, guide interventional approaches, and pro

122 hanges in host mucosal tissue and commensals posttransplant have been actively investigated, and prov

123 atients undergoing LT, 106 (12.4%) developed posttransplant HCC recurrence (median 15.8 months follow

124 Posttransplant HCC recurrence for patients with non-AFP-

125 ll-described clinicopathologic predictors of posttransplant HCC recurrence, data on prognosis followi

126 s basis, we advocate for a strategy of early posttransplant HCV eradication to facilitate use of HCV+

127 ti-viral (DAA) agents that lower the risk of posttransplant HCV recurrence but could make the patient

128 A very low incidence (1.9%) of posttransplant HHV8-related disease was observed.

129 events, and as baseline for comparison with posttransplant histology.

130 umber of muscle deficits was associated with posttransplant hospital stay (r = 0.34, P = 0.04), but n

131 ociated with reductions in pretransplant and posttransplant hyperparathyroidism, vitamin D deficiency

132 Graft-versus-host disease (GVHD) and posttransplant immunodeficiency are frequently related c

133 monstrate the potential value of using brief posttransplant immunoproteasome inhibition to entrain a

134 haploidentical grafts combined with enhanced posttransplant immunosuppression to help prevent GVHD.

135 The absence of posttransplant immunosuppression was an opportunity to d

136 HLA-barrier, with the use of an intensified posttransplant immunosuppressive therapy starting at day

137 s (N = 719) were randomized at 30 +/- 5 days posttransplant in a 1:1:1 ratio to 3 treatment groups: (

138 Anti-CMV IgG levels did not decrease posttransplant in sero (+) patients.

139 At day 14 posttransplant, increased CD11c dendritic cell accumulat

140 icantly associated with an increased risk of posttransplant infection by the same microorganism in al

141 Cryptosporidiosis is a late posttransplant infection that disseminated to biliar duc

142 hedding of donor and recipient is a risk for posttransplant infection.

143 2), hypertension (HR 0.44, P < 0.001), early posttransplant infections (HR 1.52-1.67, P = 0.007-0.03)

144 pression of T cell exhaustion molecules, and posttransplant infections in a cohort of liver transplan

145 graft function and the occurrence of serious posttransplant infections may be useful to identify KT r

146 y be valuable in prognosis and management of posttransplant infections.

147 iables identified separate pretransplant and posttransplant IR thresholds for prediction of rejection

148 y administered immunosuppressive medications posttransplant is critical to ensuring graft survival.

149 ogical surveillance pretransplant as well as posttransplant is recommended.

150 baseline out to 6 additional years (8 years posttransplant, ITT analysis, SRL/MMF, n = 34; CNI/MMF,

151 We evaluated the utility, defined as posttransplant kidney allograft lifespan, of this practi

152 eservation of transplant function at 3 years posttransplant (loss of estimated glomerular filtration

153 Optimal management of posttransplant lymphoproliferative disease (PTLD) remain

154 Nonmelanoma skin cancer, Kaposi sarcoma, and posttransplant lymphoproliferative disease have standard

155 ed with several human malignancies including posttransplant lymphoproliferative disease in immunosupp

156 The boy developed posttransplant lymphoproliferative disease, which resolv

157 patients developed hematologic malignancies (posttransplant lymphoproliferative diseases, 18; Hodgkin

158 er LT for advanced-stage PSC was 18.7%, with posttransplant lymphoproliferative diseases, colorectal

159 Posttransplant lymphoproliferative disorder (PTLD) is a

160 lassified into skin cancer, solid tumor, and posttransplant lymphoproliferative disorder (PTLD).

161 , diffuse large B-cell lymphoma (DLBCL), and posttransplant lymphoproliferative disorder (PTLD).

162 se The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) tri

163 Posttransplant lymphoproliferative disorders (PTLD) are

164 ith potential advantages in virus-associated posttransplant malignancies as well as anti-cancer prope

165 The prevention and the management of posttransplant malignancies must be considered as a main

166 romising approaches for the reduction of the posttransplant malignancies.

167 Posttransplant malignancy (PTM) is one of the leading ca

168 patient death, death-censored graft loss and posttransplant malignancy associated with the baseline s

169 L + MPA was associated with a lower risk for posttransplant malignancy in kidney allograft recipients

170 Early posttransplant malignancy is an expensive and morbid con

171 Posttransplant malignancy was classified into skin cance

172 oses, with acceptable rates of infection and posttransplant malignancy.

173 hence allow critical improvements in kidney posttransplant management.

174 performed to determine the most appropriate posttransplant medication strategy.

175 early after transplant is a risk factor for posttransplant metabolic syndrome (PTMS), cardiovascular

176 iew covers the virus-intrinsic features, the posttransplant microenvironment as well as the host immu

177 p HHV8-related disease underwent virological posttransplant monitoring by quantitative real-time poly

178 For prediction of posttransplant mortality and graft loss, 10 predictors w

179 r age groups had significantly lower risk of posttransplant mortality compared with those aged 18 to

180 pressure were not significant predictors of posttransplant mortality.

181 The primary outcome was posttransplant mortality.

182 nificantly associated with waitlist, but not posttransplant, mortality in patients with approved MELD

183 d clinical scenarios, especially in light of posttransplant nephrotoxicity and other adverse events a

184 prospective follow-up (3, 6, 12, and 24 mo), posttransplant NKG2C(+) NK cell expansions were not obse

185 Among 67 157 recipients, by 3 years posttransplant, NMSC was diagnosed in 5.7%, viral-linked

186 rall infection, and confers a higher risk of posttransplant obesity and metabolic syndrome-related co

187 ed risk of acute rejection in the first year posttransplant (odds ratio, 3.12; 95% CI, 2.13-4.57; P <

188 ected in 48 patients (49%) in the first year posttransplant, of which 11 patients (22.9%) had CMV dis

189 papillomavirus vaccines) in addition to time posttransplant or other factors.

190 ase (COX) inhibitors could improve the early posttransplant outcome after orthotopic small bowel tran

191 Posttransplant outcome analysis is not mandatory, transp

192 correlate peritransplant energy cofactors to posttransplant outcome and subsequently model this in an

193 ological lesions and of composite scores for posttransplant outcome is at best moderate.

194 biopsies could become a better predictor for posttransplant outcome than donor/recipient baseline dem

195 Energy status was correlated to posttransplant outcome.

196 n continues to remain a risk factor for poor posttransplant outcomes and does not seem to confer prot

197 sk factors to improve waitlist and long-term posttransplant outcomes in 18- to 24-year-old registrant

198 Posttransplant outcomes included 1-year estimated glomer

199 unknown, and the impact of HCV clearance on posttransplant outcomes is yet to be determined.

200 We retrospectively reviewed the posttransplant outcomes of patients who underwent haploc

201 We developed a novel score to predict posttransplant outcomes using pretransplant information

202 ter EVLP, lung grafts were transplanted, and posttransplant outcomes were compared.

203 olume, transplant hospitalization and 1-year posttransplant outcomes were not adversely affected.

204 Because of the potential impact on posttransplant outcomes, the technical complexity of tra

205 gnificant trend toward improved waitlist and posttransplant outcomes, though there is a high risk of

206 nited States, recipient selection, and their posttransplant outcomes.

207 ower likelihood of transplantation and worse posttransplant outcomes.

208 easing early kidney dysfunction and clinical posttransplant pancreatitis.

209 ailable on the efficacy of RBV-free regimens posttransplant, particularly the use of sofosbuvir (SOF)

210 ains 43 risk adjustment models for assessing posttransplant patient and graft survival and, in collab

211 ime of listing as the strongest predictor of posttransplant patient mortality.

212 onitoring pretransplant, clinical monitoring posttransplant, patient and team expectations, body imag

213 Included were 443 posttransplant patients (KT = 60, LT = 347, DLK = 36); 4

214 nitoring HLA antibodies in pretransplant and posttransplant patients despite the discrepancy between

215 n in overall mortality, including listed and posttransplant patients, of up to 676 lives.

216 y extensive beta-cell death in the immediate posttransplant period and impaired islet function in the

217 xic immunosuppressive drugs during the early posttransplant period could help to ameliorate the sever

218 have an increased risk for infections in the posttransplant period due to immunosuppressive therapy.

219 e recipients (2.1%) had viral replication in posttransplant period, one of whom developed Kaposi sarc

220 However, in the immediate posttransplant period, significantly more mild/moderate

221 pecies may play important roles in the early posttransplant period.

222 The prevalence of posttransplant, persistent hyperparathyroidism (PTH >65

223 blood hematopoietic progenitor cells and no posttransplant pharmacologic immunosuppression.

224 ecipients (OTRs), no study has estimated the posttransplant population-based incidence in the United

225 tibodies in cGVHD, we focused our studies on posttransplant production of immunoglobulin G antibodies

226 toward a more inflammatory signature as time posttransplant progressed.

227 ytes, focusing on engraftment efficiency and posttransplant proliferation and function.

228 inferior outcome was associated with delayed posttransplant recovery of NK cells expressing the HLA-C

229 ); however, the SOT-AWTX group showed faster posttransplant recovery, better intestinal graft surviva

230 stic subgroups among 106 patients developing posttransplant recurrence from 1984 to 2014, including a

231 favorable pathologic characteristics, lower posttransplant recurrence, and superior survival compare

232 and 10 comparative studies which reported on posttransplant recurrence, and there was no significant

233 ermits identification of patients at risk of posttransplant recurrence.

234 The study included 168 posttransplant renal allograft biopsies (T cell-mediated

235 ica (n = 211) had increased risk factors for posttransplant renal insufficiency at study start, relat

236 tional status is an important determinant of posttransplant resource utilization; therefore, standard

237 loreactivity, exogenous IL-22 administration posttransplant resulted in increased recovery of thymopo

238 ey transplantation may be a novel marker for posttransplant risk.

239 dates to retransplantation with a history of posttransplant SCC have a high risk of aggressive SCC.

240 Occurrence of first posttransplant SCC, melanoma, or Kaposi sarcoma of the s

241 Pretransplant and posttransplant sera from 162 lung recipients transplante

242 ersibility has been also demonstrated in the posttransplant setting and appears to be similar to what

243 CV, with decompensated cirrhosis, and in the posttransplant setting, this difficult scenario is relat

244 atients can be cured in the pretransplant or posttransplant setting.

245 However, patients with pre or posttransplant severe renal insufficiency remain more di

246 ears for several reasons, including the good posttransplant short-term results, and the lack of speci

247 nsistent predictors of cardiovascular events posttransplant (significant in 8/23 and 7/22, studies, r

248 (sub-HR [SHR], 2.60; 95% CI, 2.27-2.98), and posttransplant skin cancer (SHR, 2.92; 95% CI, 2.52-3.39

249 splant recipients who have already developed posttransplant skin cancer has not been assessed.

250 Statistically significant risk factors for posttransplant skin cancer included pretransplant skin c

251 Posttransplant skin cancer is common, with elevated risk

252 Understanding the risk factors and trends in posttransplant skin cancer is fundamental to targeted sc

253 The incidence rates for posttransplant skin cancer overall and for SCC, MM, and

254 The incidence rates for posttransplant skin cancer was 1437 per 100000 person-ye

255 Potential risk factors for posttransplant skin cancer were tested using multivariat

256 incidence and evaluate the risk factors for posttransplant skin cancer, including squamous cell carc

257 cer was associated with an increased risk of posttransplant skin cancer, PTLD, solid organ cancer, de

258 Over the first year posttransplant, SLK and LAT patients had comparable esti

259 Posttransplant smokers had higher odds of newly develope

260 Posttransplant smoking is associated with poor outcomes.

261 val, 1.46-2.02) and had significantly longer posttransplant survival (P < 0.001).

262 The expectation is to achieve comparable posttransplant survival between patients who achieve suc

263 raditionally been associated with diminished posttransplant survival due to recurrent HCV-related liv

264 interquartile range [IQR] 37-40) with 30-day posttransplant survival of 96%.

265 e five comparative studies which reported on posttransplant survival rates and 10 comparative studies

266 enefit in listed patients on VA-ECMO even if posttransplant survival remains inferior than for patien

267 n score (0, 1-9, >10, P = 0.224), comparable posttransplant survival was noted.

268 rential access to transplantation, increased posttransplant survival, and differences in health care

269 Two-year posttransplant survival, disease-free survival, and TRM

270 -LT de novo nonskin cancer decreased overall posttransplant survival.

271 ignificantly higher in KTRs who had suffered posttransplant symptomatic CMV infection in the cross-se

272 ough all patients in our series were treated posttransplant, the ideal timing of HCV therapy in this

273 By 2 years posttransplant, the incidence of CAMR was 19.4% in patie

274 ociated with poor graft and patient survival posttransplant.The objective of this supplement is to pr

275 At 5 years posttransplant, there were no significant differences in

276 Posttransplant thrombomodulin levels are elevated after

277 dependent variable to experience any type of posttransplant thrombosis (hazard ratio, 6.72; 95% confi

278 bdominal ultrasound was performed at 30 days posttransplant to capture subclinical abnormalities.

279 nsplant recipients randomized about 115 days posttransplant to convert from CNI (calcineurin inhibito

280 An IR of 1.1 or greater in posttransplant training samples and IR of 1.23 or greate

281 allocation, and choice of peritransplant and posttransplant treatment are sometimes based on the hist

282 educed their GVHD potency relative to TS1 TN Posttransplant, TS1 TEM progeny expressed higher levels

283 ho, when, and how" of feasible and effective posttransplant vaccination, frequently in the absence of

284 Pretransplant, intraoperative, and posttransplant variables were recorded.

285 Remarkably, the incidence of posttransplant viremia was reduced among cases with high

286 recipient was a significant risk factor for posttransplant viruria and viremia (OR, 4.52; CI, 2.33-8

287 malized area under the curve0-12h at month 1 posttransplant, was similar with TacHexal or Prograf; ba

288 mammalian target of rapamycin inhibition on posttransplant weight gain and the development of PTMS c

289 The odds of smoking posttransplant were 1.33 times higher in men (95% CI, 1.

290 ne use with complications at 3 and 12 months posttransplant were quantified by multivariate Cox or lo

291 ipients allows CS discontinuation from day 1 posttransplant with good tolerance and very low rejectio

292 Both patients are now over 14 months posttransplant with stable allograft function.

293 s 3%) and be rehospitalized within the first posttransplant year (78% vs 57%), all P < .001.

294 increased risk of rejection during the first posttransplant year (P = 0.0054) and to have reduced rej

295 An AMR occurred during the first posttransplant year in 31 patients (32.6%), and at one y

296 Beyond the first posttransplant year, 3% of kidney transplants fail annua

297 , respectively) and maximal within the first posttransplant year, compared with TAC-treated patients

298 wice-daily tacrolimus throughout their first posttransplant year, with (1) at least 3 blood trough le

299 and liver transplant (LT) costs in the first posttransplant year.

300 igh incidence of PTLD described in the first posttransplant year.

301 TLD in our cohort with no cases in the first posttransplant year.